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EDITORIAL
Simpliﬁcation  of  the  prophylaxis  of  endocarditis:  We
were  right!
La  simpliﬁcation  de  la  prophylaxie  de  l’endocardite  infectieuse  :  nous  avons  eu
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Infective  endocarditis  (IE)  occurs  when  a  circulating  microorganism,  originating  from  a  por-
tal  of  entry,  encounters  a  damaged  endocardium,  whether  previously  identiﬁed  or  not.  It  is
a  rare  disease,  with  an  annual  incidence  of  around  three  cases  per  100,000  individuals  and
a  stable  in-hospital  mortality  rate  of  20%  [1].  Given  the  high  morbidity  rate,  cost  burden
and  occurrence  of  post-procedure  bacteraemia,  IE  prophylaxis  strategies  have  long  beenPrevention;
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proposed  worldwide  to  patients  with  predisposing  cardiac  conditions  (PCC)  prior  to  invasive
procedures.  Since  the  early  20th  century,  clinical  ﬁndings  have  associated  streptococcal  IE,
oral  portal  of  entry,  bacteraemia  and  bacterial  engraftment  on  a  previously  damaged  endo-
cardium.  It  was  believed  that,  using  antibiotic  prophylaxis,  streptococcal  engraftment  on
a  damaged  endocardium  could,  and  should,  be  prevented,  including  after  oral  procedures
responsible  for  bacteraemia.  Prophylaxis  guidelines,  published  from  1954  until  the  early
21st  century  were  based  on  this  paradigm  [2].  They  have  expanded  to  embrace  any  type
of  procedure  (dental,  respiratory  tract,  gastrointestinal,  urogenital,  etc.)  responsible  for
bacteraemia  in  all  at-risk  patients.
In  the  context  of  weakly  supported  guidelines  and  of  oral  streptococcal  IE  incidence
decrease,  two  new  sets  of  scientiﬁc  data  challenge  the  principles  underlying  prophylaxis
guidelines  and  explain  the  general  tendency  to  reduce  prophylaxis  indications.  The  ﬁrst
set  concerns  the  relationship  between  dental  procedures  and  oral  streptococcal  IE.  No
prospective,  randomized,  placebo-controlled  study  exists  on  antibiotic  prophylaxis.  The
case-control  studies  by  Strom  et  al.  [3]  and  Van  der  Meer  et  al.  [4]  provided  evidence
that  dental  procedures  were  unlikely  to  be  a  risk  factor,  whereas  in  the  study  by  Lacassin
et  al.  [5],  scaling  and  root  canal  treatment  showed  a trend  towards  a  higher  risk  of  IE.  The
second  set  concerns  the  occurrence  of  transient  repeated  bacteraemia  from  everyday  life
activities  (tooth  brushing,  chewing,  etc.).  Whereas  preventing  bacteraemia  following  inva-
sive  procedures  was  the  pathophysiological  reasons  for  antibiotic  prophylaxis,  everyday
life  activities  were  identiﬁed  as  more  often  responsible  for  bacteraemia  than  occasional
procedures  [6].
Abbreviations: AHA, American Heart Association; IE, Infective
endocarditis; NICE, National Institute for Health and Clinical Excel-
lence; PCC, Predisposing cardiac conditions.
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In  2002,  the  French  IE  prophylaxis  guidelines  were  the
rst  to  call  a  halt  to  the  systematic  use  of  antibiotic  pro-
hylaxis  and  to  restrict  the  use  of  prophylaxis  to  patients  at
isk  of  death  from  IE,  that  is,  patients  with  high-risk  cardiac
redisposing  factors  (in  most  cases:  history  of  IE,  prosthetic
alves)  and  who  had  invasive  dental,  respiratory,  gastroin-
estinal  and/or  genitourinary  procedures  [7].  In  2007,  the
merican  Heart  Association  (AHA)  established  new  guide-
ines  [8]  that  were  a  radical  change  from  the  previous  US
nes  published  in  1997  [2]:  prophylaxis  was  no  longer  recom-
ended  before  dental  procedures  except  for  patients  with
he  highest  risk  of  adverse  outcome  resulting  from  IE  and
ho  had  undergone  ‘‘any  dental  procedure  that  involved
anipulation  of  the  oral  mucosa’’.  The  AHA  advised  against
sing  prophylaxis  in  gastrointestinal  and  urogenital  inter-
entions.  In  2008,  the  guidance  from  the  National  Institute
or  Health  and  Clinical  Excellence  (NICE)  in  the  UK  recom-
ended  that  IE  prophylaxis  should  no  longer  be  used  for  all
atients  and  before  all  procedures,  dental  and  non-dental
9].  In  2009,  the  European  Society  of  Cardiology  guidelines
10]  did  not  follow  this  radical  change,  but  recommended,
s  had  the  2007  US  guidelines  [8],  the  pursuit  of  antibiotic
rophylaxis  for  dental  procedures  solely  in  patients  at  high-
st  risk  (prosthetic  heart  valves,  congenital  heart  disease
nd  history  of  IE).  Prophylaxis  was  no  longer  recommended
or  patients  at  moderate  risk  or  those  deemed  at  low  risk
pacemakers  and/or  deﬁbrillators  or  who  had  had  previous
oronary  artery  bypass  graft  surgery)  [10].
IE  antibiotic  prophylaxis  had  thus  been  drastically  mod-
ﬁed,  not  because  its  ineffectiveness  had  been  proven,
ut  because  the  pathophysiology  supporting  its  use  was  no
onger  convincing.  There  are  currently  two  distinct  IE  pro-
hylaxis  positions:  the  radical  British  position  based  on  the
ack  of  evidence  of  IE  efﬁcacy  and  which  abandoned  all
ntibiotic  prophylaxis;  and  the  more  mitigated  one,  adopted
y  the  ‘‘remaining  world’’:  considering  that  the  lack  of
vidence  is  not  evidence  of  ineffectiveness,  recommending
ntibiotic  prophylaxis  only  for  a  limited  patient  population,
hose  at  very  high  risk  of  death  in  case  of  IE.  These  positions
ave  generated  considerable  reactions,  both  in  favour  of
aintaining  the  antibiotic  prophylaxis  because  there  is  no
angible  evidence  for  a  change,  and  in  favour  of  an  abandon
r  a  limitation  because  there  is  no  tangible  evidence  for  its
ontinuation  [11].
However,  the  adequacy  of  these  IE  prophylaxis  guideline
odiﬁcations  remains  questionable:  a  signiﬁcant  increase
n  IE  incidence  after  scaling  down  prophylaxis  use  would
rgue  for  its  efﬁcacy,  whereas  a  stable  or  decreased  IE
ncidence  would  tend  to  support  the  appropriateness  of  pro-
hylaxis  modiﬁcations.  In  2011,  Thornhill  et  al.  [12]  reported
n  evaluation  of  guideline  modiﬁcations.  They  conducted
n  epidemiological  study  in  England  after  the  2008  NICE
uidelines,  using  the  2000—2010  national  data  on  inpatient
ospital  activity  [12]. During  the  2  years  following  the  guide-
ine  changes,  antibiotic  prophylaxis  prescription  decreased
y  78%,  without  evidence  of  an  upward  trend  in  IE  cases
in  particular  of  oral  streptococcal  IE)  or  in  death  rate.  In
rance,  results  of  three  population-based  surveys  showed
hat  streptococcal  IE  incidence,  with  or  without  previously
dentiﬁed  native  PCC,  did  not  increase  between  1999  and
008,  following  2002  guideline  modiﬁcations  [13]. This  lack
f  increase  was  also  reported  in  the  US  by  Desimone  et  al.Editorial
14]  in  Olmsted  County  and  in  the  US  paediatric  population
y  Pasquali  et  al.  [15].
Two  different  IE  patterns  can  be  distinguished:
streptococcal  community-acquired  IE  for  which  antibi-
otic  prophylaxis  is  recommended  in  high-risk  patients  who
undergo  a  dental  procedure  (with  the  notable  exception
of  the  NICE  guidelines);
staphylococcal  community  and  healthcare-acquired  IE  for
which  no  speciﬁc  prevention  recommendation  exists.
Present  data  establish  that  the  recent  modiﬁcations  in
ntibiotic  prophylaxis  strategy  are  not  at  the  origin  of
 short  term  re-emergence  of  IE  due  to  dental  microor-
anisms.  Before  continuing  to  limit  antibiotic  prophylaxis
se  and  recommending  —– as  NICE  did  —– that  no  antibiotic
rophylaxis  be  used  in  any  patients,  it  would  be  wise  to
ontinue  monitoring  the  epidemiological  disease  character-
stics  with  population-based  studies,  to  better  understand
he  relationship  between  oral  ﬂora,  dental  status  and  at-
isk  procedures,  and  to  evaluate  doctors’  and  dentists’
ompliance  with  the  guidelines.  Global  hygiene  measures  for
verybody,  including  oral  and  skin  hygiene,  to  minimize  the
isk  of  community-acquired  and  healthcare  facility-acquired
acteraemia  must  be  reinforced,  and  must  target  patients
oth  with  and  without  PCC,  and  be  included  in  a  global
trategy  of  infection  prevention.
IE  co-evolved  with  socioeconomic  changes  and  medical
rogress,  leading  to  an  increase  in  onset  age,  comorbidities,
ntracardiac  devices  and  of  staphylococcal  IE.  IE  antibiotic
rophylaxis  has  been  drastically  modiﬁed  during  the  last  10
ears,  and  there  are  currently  two  opposite  strategies,  both
f  then  leading  to  a  major  reduction  in  antibiotic  prophy-
axis  indications.  To  date,  this  change  has  not  given  rise  to
n  increase  in  oral  streptococci  IE,  which  supports,  a  posteri-
ri,  the  reduction  of  its  use  and  allows  us  to  claim  that  ‘‘we
ere  right’’.  A  better  understanding  of  the  physiopathol-
gy  of  IE  and  the  characterization  of  the  new  valvulopathies
hould  help  to  better  target  patients  not  previously  consid-
red  at  risk  of  IE.  Nevertheless,  epidemiological  surveillance
s  vital  in  order  to  observe  rapid  changes  in  the  proﬁle  of
he  disease  and  to  modify,  if  necessary,  recommendations
or  better  prevention.
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